Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (797)	5/2/2003 8:00:47 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3559

<<Normaly, REGN will wait until they complete PIII trial(s), and IF positive they will say: We have more potent candidate!>> And maybe than, they may start to look at other candidates! Proc. Natl. Acad. Sci. USA, Vol. 100, Issue 9, 5028-5033, April 29, 2003 Applied Biological Sciences Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 Rebekah R. White, Siqing Shan, Christopher P. Rusconi, Geetha Shetty§, Mark W. Dewhirst, Christopher D. Kontos§, and Bruce A. Sullenger,¶ Departments of Surgery, Radiation Oncology, and § Medicine, Duke University Medical Center, Durham, NC 22710 Communicated by Jennifer A. Doudna, University of California, Berkeley, CA, and approved February 26, 2003 (received for review October 22, 2002) Angiopoietin-2 (Ang2) appears to be a naturally occurring antagonist of the endothelial receptor tyrosine kinase Tie2, an important regulator of vascular stability. Destabilization of the endothelium by Ang2 is believed to potentiate the actions of proangiogenic growth factors. To investigate the specific role of Ang2 in the adult vasculature, we generated a nuclease-resistant RNA aptamer that binds and inhibits Ang2 but not the related Tie2 agonist, angiopoietin-1. Local delivery of this aptamer but not a partially scrambled mutant aptamer inhibited basic fibroblast growth factor-mediated neovascularization in the rat corneal micropocket angiogenesis assay. These in vivo data directly demonstrate that a specific inhibitor of Ang2 can act as an antiangiogenic agent.